Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/81286
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Parker, W. | - |
dc.contributor.author | Yeoman, A. | - |
dc.contributor.author | Jamison, B. | - |
dc.contributor.author | Yeung, D. | - |
dc.contributor.author | Scott, H. | - |
dc.contributor.author | Hughes, T. | - |
dc.contributor.author | Branford, S. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | British Journal of Cancer, 2013; 109(6):1593-1598 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.issn | 1532-1827 | - |
dc.identifier.uri | http://hdl.handle.net/2440/81286 | - |
dc.description.abstract | <h4>Background</h4>BCR-ABL1 mutation analysis is recommended for chronic myeloid leukaemia patients. However, mutations may become undetectable after changing therapy, and it is unknown whether they have been eradicated.<h4>Methods</h4>We examined longitudinal data of patients with imatinib-resistant mutations, which became undetectable by Sanger sequencing to determine whether mutations could reappear, and the related circumstances.<h4>Results</h4>Identical imatinib- and nilotinib-resistant mutations reappeared following further therapy changes in five patients, and was associated with subsequent nilotinib resistance in four.<h4>Conclusion</h4>The data suggest that some BCR-ABL1 mutations may persist at undetectable levels for many years after changing therapy, and can be reselected and confer resistance to subsequent inhibitors. | - |
dc.description.statementofresponsibility | W T Parker, A L Yeoman, B A Jamison, D T Yeung, H S Scott, T P Hughes, and S Branford | - |
dc.language.iso | en | - |
dc.publisher | Nature Publishing Group | - |
dc.rights | © 2013 Cancer Research UK. All rights reserved. | - |
dc.source.uri | http://dx.doi.org/10.1038/bjc.2013.318 | - |
dc.subject | chronic myeloid leukaemia | - |
dc.subject | mutation analysis | - |
dc.subject | tyrosine kinase inhibitor | - |
dc.subject | resistance | - |
dc.title | BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1038/bjc.2013.318 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Yeung, D. [0000-0002-7558-9927] | - |
dc.identifier.orcid | Scott, H. [0000-0002-5813-631X] | - |
dc.identifier.orcid | Hughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509] | - |
dc.identifier.orcid | Branford, S. [0000-0002-1964-3626] [0000-0002-5095-7981] | - |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.